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Background. Duplex ultrasonography (DUS) can be used for treatment planning for lower extremity
peripheral arterial disease (PAD), but has not replaced contrast-enhanced imaging such as computed
tomography angiography (CTA). We assessed DUS-based treatment planning for consistency, confidence,
and the value of additional CTA among multinational surgeons.
Methods. Data from 12 patients with PAD were reviewed by 2 American vascular surgeons individually
and 1 Dutch vascular department by consensus. Reviewers selected treatment based on DUS first and
based on added CTA second. Agreement and consistency of treatment plans was assessed using kappa
statistics (k). Imaging quality and therapeutic confidence were scored (1–5) and assessed with t-tests.
Results. Of the 36 treatment plans formulated, additional CTA confirmed 27 (75%), changed 6
(17%), and supplemented 3 (8%) plans. The approach never changed when open revascularization
was selected based on DUS (14 plans; 39%). Agreement between DUS- and CTA-based treatment
planning was substantial, with a mean kappa (mk) of 0.68, but agreement between reviewers was fair
(mk DUS, 0.24; mk CTA, 0.23). CTA received greater average scores than DUS for quality (4.36 vs
3.29; P < .0001) and confidence (4.36 vs 3.26; P < .0001). Reviewers often expressed the need for
additional imaging after DUS (mean, 63%).
Conclusion. PAD treatment planning based on CTA was mostly consistent with DUS-based treatment
plans, although CTA was still felt to be needed to increase confidence. This observation suggests that to
promote greater use of less invasive DUS imaging, not only improvement of DUS quality but also
improvement of clinician confidence is required. (Surgery 2014;156:492-502.)From the Division of Vascular and Endovascular Surgery,a Department of Surgery, Brigham and Women’s
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URGERYTREATMENT PLANNING for peripheral arterial disease
(PAD) of the lower extremities requires accurate
anatomic depiction of the vasculature. Angiog-
raphy has long been the conventional imaging mo-
dality, but this technique is invasive and requires
arterial puncture, intravascular administration of
contrast, and radiation exposure and is further-
more associated with local and systemic complica-
tions with the resulting additional care needed.1-3
In an increasing number of European institutions,
angiography has been replaced by less invasive im-
aging techniques, such as Duplex ultrasonography
(DUS), computed tomography angiography
(CTA), or magnetic resonance angiography.4,5
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modality that does not require contrast or radia-
tion exposure, as do angiography, CTA, and mag-
netic resonance angiography. When DUS was
introduced in the 1980s, studies demonstrated
that agreement between DUS and angiography
was just as good as agreement between 2 clinicians
who read the same angiograms both for detecting
lesions and planning treatment.6-8 In subsequent
years, more studies demonstrated that DUS can
be a safe alternative to angiography.9-13 More
recent publications advocate for an imaging work
up with DUS only for PAD patients, because DUS
has been shown to be a reliable tool for treatment
planning.3,4,14,15 Nonetheless, the use of DUS is
low in the United States,16 and routine use of
DUS as the sole imaging modality before interven-
tion has, with the exception of some centers,3,15
not been accepted widely.
One of the barriers to greater adoption of DUS
that has been described is the lack of confidence that
clinicians seem to have in DUS, which further results
in frequent orders for additional imaging.17 Several
factors contribute to this lack of confidence,
including the operator dependency and manner of
presentation of DUS results. Although for the assess-
ment of hemodynamic impact of arterial lesions,18,19
DUS is less subjective than still images, DUS is depen-
dent on the technician for interpretation and docu-
mentation of the examination. In addition, DUS
results are presented in a written report, sometimes
accompanied by color Doppler images; clinicians,
however, are more familiar with images that more
closely resemble a ‘‘roadmap’’ of the arterial vascula-
ture, as provided by CTA or angiography.1,17,20 To
counter this problem, vascular diagnostic labora-
tories include a graphic presentation of the DUS
findings in a map of the arterial system, often
referred to as arterial mapping.13
Based on clinical experience, we hypothesized
that, not infrequently, additional imaging is or-
dered for the benefit of the treatment planning
and therapeutic confidence of the clinicians. The
purpose of this pilot study was to assess treatment
planning based on DUS and based on additional
imaging with CTA for consistency and confidence.
We expected that both imaging modalities would
be affected similarly by interobserver variability in
treatment planning and that added CTA imaging
would increase clinician confidence rather than
affect the actual PAD treatment plan.
METHODS
Study cohort. The study protocol was approved
by the Medical Ethics Committee of the Dutch andAmerican hospitals. This study cohort consisted of
12 patients with claudication or critical limb
ischemia who were presented consecutively at a
weekly meeting of vascular surgeons and interven-
tional radiologists at a tertiary teaching hospital in
The Netherlands. These patients had undergone a
routine work up for PAD at their center that
included both DUS and CTA imaging. Patients
with acute ischemia and acute limb threat were
excluded. Those who were unable to undergo DUS
or CTA imaging (eg, owing to extensive wounds or
contrast allergy) or who did not receive both
imaging modalities within a 1-month period of
time were also excluded.
Dutch clinicians. After the clinical presentation
of each case at the meeting, clinicians first formu-
lated a treatment plan based on the findings of the
DUS examination presented in a written report
and arterial map. Subsequently, CTA imaging was
added, and the clinicians decided on a treatment
plan based on this CTA. The confidence in both
treatment plans was scored on a numerical scale of
1 to 5, with 1 being least confident and 5 being
most confident. The same scoring scale was used to
score the imaging modalities for imaging quality.
All decisions were made by consensus of the
clinicians at the meeting, including faculty and
senior residents of vascular surgery and interven-
tional radiology.
American clinicians. The same patient data
(anonymized and translated into English) were
presented to 2 vascular surgeons at a tertiary
teaching hospital in the United States with an
average experience of >10 years in practice. A
third U.S. vascular surgeon was excluded at an
early stage, because we felt that our study protocol
was not being met. This reviewer showed a dis-
proportionally high level of discomfort with DUS-
based treatment selection, which resulted in the
selection of a conservative approach for nearly all
DUS-based treatment plans. Furthermore, this
reviewer commented that the selected conservative
approach represented actually the wish to not
make a decision at all and to proceed to conven-
tional angiography instead, which we deemed not
to be representative of the clinical decision-making
process that we set out to assess in our study.
Neither DUS nor CTA were standard work up for
PAD because angiography was the routinely used
imaging modality for these patients at their center.
Similar to the Dutch part of this study, the U.S.
surgeons selected treatment strategies based first
on DUS and second on the CTA and scored each
for quality and confidence. After a DUS-based
treatment was selected, the U.S. reviewers were
Fig. Duplex ultrasonography (DUS) arterial map. Results of the DUS examination are drawn onto a map of the arterial
vasculature. EAI, Dutch abbreviation for Ankle Branchial Index (ABI).
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ing to be required. For collection and manage-
ment of the U.S. data, we utilized the study data
REDCap electronic data capture tool hosted at
Partners Healthcare and the Brigham and
Women’s Hospital (Appendix I, available online).1
Imaging protocols. A vascular ultrasonography
technician with >20 years of experience per-
formed DUS exams using a Siemens Acuson
S2000 ultrasonography machine. With an insona-
tion angle of <608, a 3.5-MHz curved array, and a
7.5-MHz linear transducer were used for aorto-
iliac segments and femoral, popliteal, and crural
segments respectively. Ankle-brachial indexes were
computer-calculated using the ankle artery with
the greatest maximal systolic acceleration
(maximal slope of the Doppler curve in the early
systolic phase).21 The peak systolic velocity (PSV)
was determined in 14 adjacent locations, of which
7 were in the aorto-iliac segments and another 7
in the femoropopliteal segments and PSV ratioswere calculated if the PSV was >2.0 m/s. The
Dutch vascular diagnostic laboratory uses the
following criteria for PSV ratios: PSV ratio of
>2.4 indicates a stenosis of $50% and a PSV ratio
of >5.4 indicates a stenosis of $75%. DUS find-
ings are documented in a written report and
drawn onto a map of the arteries of the lower ex-
tremities (Fig). CTA of the lower limbs was
performed using a Toshiba Aquilion-64 or
Aquilion-one. A scan is acquired from the celiac
trunk to the tibia platform (1 mm), followed by
0.5-mm coupes extending from the femoral con-
dyles to the feet. The first part of scanning was
operated at 120 kV and dosis modulation and
the second part at 100 kV at fixed mA (100 mA).
Scans were acquired with a helical pitch of 5.3 in
the 64-slice mode (64 3 0.5 mm). The start of
the scan was determined by bolus-triggering
measured in the abdominal aorta. Contrast
administration involved intravenous injection of
120 mL of contrast medium (I370) at 4 mL/s.
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and CTA-based treatment plans and interobserver
agreement for treatment planning on DUS or CTA
were calculated using kappa (k) statistics with 95%
CIs. Agreement was calculated based on the actual
treatment plans (eg, bypass graft procedure or
endarterectomy). For interpretation of k-values,
the following categories for agreement were used:
Less than chance (k < 0), slight (k = 0.01–0.20),
fair (k = 0.21–0.40), moderate (k = 0.41–0.60),
substantial (k = 0.61–0.80), and almost perfect
agreement (k = 0.81–0.99).22 Scores for quality and
confidence on DUS and CTA were assessed per
reviewer (signed rank test), between reviewers
(Friedman analysis of variance by ranks), and over-
all (mixed (random and fixed effects) methods
linear models to account for clustering per pa-
tient). In addition, DUS quality and confidence
scores and clinical factors of cases for which the
DUS-based treatment plan was impacted by the
addition of CTA were investigated separately using
mixed linear models. Data management and ana-
lyses were performed using SAS 9.3 (SAS Institute
Inc, Cary, NC).
RESULTS
Cohort. Of the 12 patients included in this study,
9 (75%) were claudicants, and 3 (25%) were critical
limb ischemia patients with rest pain and no tissue
loss. Mean age was 61 years (range, 42–73) and 10
(83%) were men. The most common comorbidities
were coronary artery disease (33%), diabetes (25%),
and hypertension (25%).Most patients were known
to have PAD (8 patients; 67%), and all of those had
received previous exercise therapy (25%), endovas-
cular revascularization (33%), or open operative
revascularization (17%).
Impact of added CTA on the treatment strategy.
Our 3 reviewers formulated treatment strategies
for our cohort of 12 patients, which resulted in 36
treatment strategies (3 3 12) that consisted of a
DUS-based treatment plan and a plan based on the
added CTA. In 27 strategies (75%), CTA plans
were consistent with the DUS-based treatment
plans. In 6 strategies (17%), CTA changed the
DUS-based strategies. More specifically, 5 treat-
ment plans (14%) for conservative management
were turned into interventions, and 1 endovascular
revascularization (3%) was turned into an open
surgical approach owing to the addition of CTA
(Table I). The added CTA never impacted or
changed the approach when open operative treat-
ment had been selected based on DUS, which was
the case in 14 treatment strategies (39%). Another
strategies 3 (8%) were not changed but merelysupplemented owing to added CTA as follows: A
PTA treatment plan was supplemented with an
open surgical bypass and endarterectomy, a plan
for endarterectomy was supplemented with a stent
procedure, and a treatment plan for bypass and
stenting was supplemented with endarterectomy.
Overall, the 9 treatment strategies (25%) that
were impacted by the addition of CTA, either
changed or supplemented, were distributed over
6 individual patients (patients 1, 3, and 10 for 2 re-
viewers; and 9, 11, and 12 for 1 reviewer). Analysis
of patient and clinical factors that might predict
impact for CTA showed no association.
Agreement between treatment plans. Agree-
ment between plans that reviewers based on DUS
with plans based on CTA resulted in a mean kappa
value of 0.68, which corresponds to substantial
agreement (k reviewer(r)1, 0.85 [95% CI, 0.57–1.13];
kr2, 0.61 [95% CI, 0.33–0.90]; kr3 0.58 [95% CI,
0.28–0.88]; Table II). Agreement between re-
viewers was less and showed similar mean kappa
values for treatment planning based on DUS
(mean k, 0.24) and based on CTA (mean k, 0.23).
Quality and confidence. CTA received greater
mean scores for quality (4.4 vs 3.3; P < .0001) and
confidence for treatment planning (4.4 vs 3.3; P <
.0001) than DUS (Table III). Whereas all mean
quality scores were greater for CTA than for
DUS, this difference was only significant for
reviewer 2 (U.S.), who scored CTA highly. Thera-
peutic confidence scores of U.S. reviewers were
significantly greater on CTA than on DUS. For
the Dutch group of clinicians, the difference in
confidence scores for the 2 modalities was not sig-
nificant (CTA 4.6 vs DUS 4.0; P = .2500). Among
reviewers, scoring behavior was significantly
different for all quality and confidence scores
with the exception of DUS quality, which received
low scores in a more similar fashion. The mean
therapeutic confidence score of the reviewers
based on DUS showed an average increase of
30% with the addition of CTA (3.3 to 4.4; P <
.0001).
Lesser scores for quality and confidence corre-
sponded to the impact of CTA, because cases for
which CTA affected the DUS-based treatment
strategy had lesser mean scores than cases for
which the strategy was not affected by added CTA
(quality, 2.5 vs 3.5; confidence, 2.6 vs 3.5). These
affected cases were associated with lesser quality
of DUS (P < .0001) and lesser confidence of DUS
(P = .028) while accounting for different reviewers.
Furthermore, all reviewers scored DUS quality and
confidence of these cases with 1 point less than
their own average for these DUS scores.
Table I. Duplex ultrasonography (DUS)- and computed tomography angiography (CTA)-based treatment
plans
Patient
Reviewer 1 (USA) Reviewer 2 (USA) Reviewer 3 (The Netherlands)
DUS CTA DUS CTA DUS CTA
1 Endo (PTA/s) Open* Open Open Conservative Endo (PTA)y
2 Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s)
3 Open Open Endo (PTA) Both (PTA/s/e/b) * Conservative Endo (PTA)y
4 Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s)
5 Open Open Endo (PTA) Endo (PTA) Endo (PTA) Endo (PTA)
6 Open Open Both (PTA/s/e) Both (PTA/s/e) Endo (PTA/s) Endo (PTA/s)
7 Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s) Endo (PTA/s)
8 Open Open Both (PTA/s/b) Both (PTA/s/b) Open Open
9 Open Open Both (PTA/s/b) Both (PTA/s/e/b)z Conservative Conservative
10 Endo (PTA/s) Endo (PTA/s) Conservative Both (PTA/s/e)y Conservative Endo (PTA)y
11 Open Open Both (PTA/s/e/b) Both (PTA/s/e/b) Conservative Openy
12 Open
(endarterectomy)
Open
(endarterectomy)
Open
(endarterectomy)
Both (PTA/s/e)x Both (t/e) Both (t/e)
*CTA converted endovascular approach into open surgical approach.
yCTA converted conservative management into an intervention (either endo, open or both).
zApproach did not change but the treatment plan of a stent and bypass procedure was supplemented with an endarterectomy.
xCTA complemented open surgical strategy with an additional endovascular procedure.
Conservative includes medical treatment, exercise therapy, and conservative management, Endo includes PTA and PTA with stent, and open includes bypass
graft procedure, endarterectomy and thrombectomy.
PTA, percutaneous transluminal angioplasty.
Table II. Agreement between Duplex ultrasonography (DUS)- and computed tomography angiography
(CTA)-based treatment planning
Agreement Kappa value [95% CI]
DUS- and CTA-based treatment planning
Reviewer 1 (USA1) 0.85 [0.57–1.00]
Reviewer 2 (USA2) 0.61 [0.33–0.90]
Reviewer 3 (NL) 0.59 [0.30–0.88]
Mean .68
DUS-based planning
Reviewer 1 with 2 0.21 [0.04 to 0.47]
Reviewer 1 with 3 0.19 [0.02 to 0.39]
Reviewer 2 with 3 0.32 [0.08–0.57]
Mean .24
CTA-based planning
Reviewer 1 with 2 0.23 [0.04–0.42]
Reviewer 1 with 3 0.26 [0.03–0.50]
Reviewer 2 with 3 0.19 [0.04–0.42]
Mean .23
USA1 and USA2, U.S. clinician 1 and 2; NL, Dutch clinicians by consensus.
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geons expressed the need for additional imaging
in 10 (83%) and 5 (42%) cases, respectively (63%
on average), and they indicated that the subse-
quently added CTA provided them with informa-
tion they had found lacking on DUS in nearly all
cases (70% and 100%, respectively). Of the 15
cases in which a reviewer had requested additional
imaging, only 4 were impacted subsequently by the
added CTA. More specifically, of the 10 (reviewer1) and 5 (reviewer 2) requests for additional
imaging, the subsequently added CTA impacted
the treatment approach for 1 (10%) and 3 (60%)
of these cases. The reasons for additional imaging
requests ranged from a general lack of confidence
in the DUS examination for a certain area to the
need for more specifics to better assess the
possibility of endovascular therapy (Appendix II,
available online). Together, the 2 U.S. reviewers re-
quested additional imaging in 15 cases, of which 7
Table III. Quality and confidence scores for Duplex ultrasonography (DUS) and computed tomography
angiography (CTA)
DUS, mean (SD; range) CTA, mean (SD; range) P value*
Diagnostic quality per reviewer
Reviewer 1 3.2 (0.4; 3–4) 3.8 (0.8; 2–5) .0098
Reviewer 2 3.3 (1.1; 1–5) 4.9 (0.3; 4–5) .0020y
Reviewer 3 3.5 (1.4; 1–5) 4.3 (1.0; 3–5) .0125
Scores among reviewersb
Reviewer 1 vs 2 vs 3
DUS .410
CTAy .005
All reviewers (overall means) 3.3 (1.0; 1–5) 4.4 (0.9; 2–5) <.0001y
Therapeutic confidence (per reviewer)
Reviewer 1 3.0 (0.9; 1–4) 3.9 (0.8; 2–5) .0020y
Reviewer 2 2.9 (0.7; 2–4) 4.7 (0.5; 4–5) .0005y
Reviewer 3 4.0 (1.3; 1–5) 4.6 (0.7; 3–5) .2500
Scoring among reviewers
Reviewer 1 vs 2 vs 3
DUS .0001y
CTA .0006y
All reviewers (overall means) 3.3 (1.0; 1–5) 4.4 (0.7; 2–5) <.0001y
*Alpha = 0.05.
ySigned rank tests were used for score comparisons per reviewer and Friedman analysis of variance by ranks for scores between reviewers. Mixed linear
models were used to account for patient clustering in the comparison of overall mean scores.
sd, Standard deviation.
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formation or visualization on DUS,’’ another 7 as
‘‘the need for more specifics or detail to allow for
treatment planning,’’ and one regarded an issue
of low confidence only.
DISCUSSION
In this pilot study, treatment planning of clini-
cians was largely consistent between DUS the
addition of a CTA but subject to variability among
different reviewers. Although clinicians often felt
additional imaging was needed for more specifics
and confidence, added CTA did not impact the
majority of treatment plans. The level of agree-
ment between DUS- and CTA-based planning has
not been investigated before, but our kappa values
for substantial agreement are consistent with,8,23,24
or even less than,25-27 prior publications on DUS-
based treatment planning that used angiography
as the reference test. Moreover, the added CTAs
in our study did not affect any of the DUS-based
plans for open operative treatment, which sup-
ports the previously demonstrated utility of DUS
in planning for open operative revascularization.28
Impact of additional CTA. From a clinical point
of view, it is important to appreciate the impact of
an additional CTA on the ‘‘conservative,’’ ‘‘endo-
vascular,’’ or ‘‘open surgical’’ approach that was
selected based on DUS. An endovascular plan wasconverted into an open surgical approach in only 1
case. Such a conversion is considered less harmful
than a shift in the opposite direction, which never
occurred in our study, because all DUS-based plans
for open operative revascularizations were not
affected and merely confirmed by additional CTA.
Clinician confidence. Additional CTA did
change the DUS-based plans for a conservative
approach into an interventional approach.
Remarkably, all but one of those changes had
been selected by Dutch reviewers, who showed no
difference between confidence on DUS and on
CTA, as did the U.S. reviewers; however, we can
note that the Dutch clinicians also expressed the
need frequently for additional imaging at the
Dutch multidisciplinary meeting. Their residents
being less experienced have particularly expressed
the need for additional imaging to confidently
formulate a treatment strategy. This observation
could imply that their initial selection of a conser-
vative approach was reflective of a lack of confi-
dence to select a more invasive, interventional
approach. Our result of a 30% mean increase in
confidence scores owing to added CTA is difficult
to interpret, but given the frequent requests for
additional imaging, this observation could imply
that this increase in confidence is relevant to
clinicians. Yet, the correlation between confidence
and orders for additional imaging does differ per
Surgery
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requested additional imaging in many cases, but
these requests did not seem to correlate well with
the actual impact of the added CTA imaging. The
other reviewer predicted an impact of added
imaging better, and his expressed need for addi-
tional imaging (42%) was in line with estimates of
previous studies that assessed the need for addi-
tional imaging after DUS.10,17
Limitations. The small sample size and the use
of a single vascular technician limit markedly the
generalizability of our results to other centers. We
also recognize that, particularly for the U.S. re-
viewers, artificial circumstances of the study design
can be a limitation compared with real-world
practice, because collecting one’s own medical
history and physical examination data would affect
greatly confidence in imaging. In an effort to best
inform the U.S. reviewers in this study, we provided
them with written documentation of all clinical
information of cases as presented at the Dutch
meeting. Based on prior publications, our findings
might even underestimate the potential of DUS for
treatment planning, and the value of additional
imaging might even be of less than found in this
study.3,12,25-27 The variability in treatment planning
and scoring behavior of reviewers is an important
limitation of this study. This variability might
partially be the result of our multinational study
design and the fact that one reviewer’s decisions
were based on consensus, whereas others decided
individually. We realized that the U.S. reviewers
had a lesser comfort level with DUS at baseline
compared with the Dutch surgeons, for whom
DUS is more common practice for these patients.
Yet, we deliberately chose to include both the
Dutch and U.S. reviewers, because this enabled
us to assess DUS- and CTA-based planning in set-
tings with different utilization rates of these imag-
ing types. Uncertainty and unfamiliarity among
these reviewers might have contributed to a
greater variability for treatment planning; however,
interobserver agreement was not greater between
surgeons of the same nationality, because agree-
ment on treatment planning was not necessarily
greater between the U.S. reviewers. Furthermore,
we chose to compare the individually composed
treatment plans of the U.S. surgeons with the
Dutch consensus-based plans, because we wanted
to assess treatment planning as close to the real
clinical practice settings as possible. In the United
States, surgeons formulate treatment plans for
their patients more autonomously, whereas in the
Dutch institution, treatment plans seem to be the
result of group evaluation based on consensus ofcolleagues. In fact, the Dutch patients had received
the final treatment plan formulated at the Dutch
meeting, which is the CTA-based plan of the Dutch
surgeons in our study. A potential for bias may
have occurred in the study design that presented
clinicians with DUS first and then added CTA. In
this manner, greater confidence on CTA could
also be the result of more imaging, and the DUS-
based treatment planning might be affected by
the knowledge that additional CTA will follow any-
way. Although it is true that more imaging will
probably create more confidence, the question of
this study was not so much how clinicians score
confidence on CTA, but rather (1) whether clini-
cians would have enough information and confi-
dence on DUS alone to allow for treatment
planning; and (2) what the impact of additional
imaging would be. If clinician confidence on
DUS is too low, additional imaging will be
required, regardless of the associated costs, time,
and invasiveness. Although our DUS technician
was very experienced, both U.S. and Dutch clini-
cians often expressed the need for additional im-
aging, which implies that the DUS examinations
often did not meet the expectations of clinicians
and the requirements of clinical decision making.
As in many other publications in this field, we
highlight the need for internal validation of tech-
nicians, clinicians, and a close relationship be-
tween these 2 before adopting a workup with
DUS only, because the utility of DUS is known to
be dependent on the skills of technicians and con-
fidence and trust of clinicians.3
Future directions and recommendations. While
recognizing variability between centers and clini-
cians, this study identified the obstacle of clinician
confidence as a factor that could hamper greater
use of DUS in the appropriate clinical settings. We
suggest that sites that are looking to use DUS more
often before PAD interventions might want to start
with a workup that includes both DUS and another
imaging modality such as CTA to improve famil-
iarity and confidence with less invasive imaging. In
this manner, they can first match the technical
aspects of the DUS results with the confidence of
the surgeons on the user end to finally be able to
have a work up with DUS alone as the initial tool
for decision making.13 Greater adoption of DUS
can be beneficial to both patient safety and health
care costs because this inexpensive modality limits
patient exposure to intravenous contrast agents
and radiation, and saves the expense of care for
contrast-associated complications. At the same
time, it is important to realize that additional fac-
tors will influence institutional utilization of
Surgery
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which may be different for vascular surgeons prac-
ticing in different systems of health care and
compensation.16 We suggest that for the U.S. sur-
geons practicing in a fee-for-service environment,
financial factors may have greater influence than
for the salaried Dutch surgeons.
We believe this work illustrates that, although
clinicians might be able to plan PAD treatment
based on DUS alone, clinician confidence is an
important impediment to relying on DUS alone in
the decision-making process. Greater use of DUS
as an initial decision-making tool may help to
decrease the number of redundant imaging
studies that are associated with additional costs,
time, and invasiveness. The variability found in
treatment planning, clinician confidence, and re-
quests for additional imaging demonstrate the
complexity of the clinical decision-making process
with PAD. Although studies on the decision mak-
ing process of clinicians are cumbersome, larger
studies are required to better understand the
clinician’s motivation to order additional imaging
and to explore the potential for DUS to serve as a
primary decision tool.REFERENCES
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Appendix I. Survey for treatment selection on duplex ultrasonography (DUS) and computed tomography
angiography (CTA)
Question Possible answers/data included
Patient information Age, gender, location and type of complaints, duration of
symptoms, pain free walking distance, rest pain, tissue
loss, disability, mobility aid, pulsations, ABIs,
Rutherford stage, previous vascular diagnoses and
procedures, comorbid history (AP, CAD, AMI,
pacemaker, CHF, valvular disease, stroke), risk factors
(smoker, hypertension, hyperlipidemia, diabetes, renal
failure, pulmonary disease).
Treatment strategy (I) based on DUS
1. Diagnostic quality score 1–5
2. Treatment plan (multiple answers possible) Medical treatment, exercise therapy, conservative;
Endovascular, PTA; Endovascular, PTA with stent;
surgery, thrombectomy; surgery, endarterectomy;
surgery, bypass graft procedure
3. Therapeutic confidence (confidence in selected
treatment plan)
1–5
4. Do you consider additional imaging to be required? Yes/no. If yes, do you consider additional imaging to be
required. Please explain why and which necessary
information was missing in the duplex results.
Treatment strategy (II) based on CTA
If question 4 = yes, did this additional imaging provide
you with the information you found to be lacking on
the duplex?
Yes/no
If yes, the additional imaging provided you with
information that was lacking. Please specify what
additional valuable information.
<open text field>
Questions 1–3 repeated.
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Appendix II. Rationale for additional imaging requests of the U.S. reviewers
Patient Reviewer 1 Reviewer 2
After DUS: Why is additional imaging required? After DUS: Why is additional imaging required?
After CTA: What information that was lacking is now
provided ?
After CTA: What information that was lacking is now
provided?
1 Aortic bifurcation is unclear in the DUS Considered not required
Aortic bifurcation is clear and EIA disease is now seen
2 Not confident about DUS for iliacs Considered not required
More confident about common iliac artery
3 Not sure about suitability of targets for bypass Incomplete anatomic DUS assessment, incomplete
data about the iliofemoral vessels
Additional information not provided Full visualization of blood vessels, extent of plaque, and
degree of calcification on aorto-iliac-femoral level
4 To determine extent of iliac disease Considered not required
This can now can be determined
5 To determine extent of prior stent into popliteal artery Considered not required
This can now be determined
6 Evaluation of above- vs below-knee popliteal artery Considered not required
Popliteal target can now be determined
7 Considered not required Considered not required
8 Evaluate possible flush occlusion in SFA and the quality
of left EIA for supporting graft
Required for definitive therapeutic decision, to
confirm specifics of multilevel disease and
involvement of CFA
Additional information not provided Precise degree of iliac disease, proximity to inguinal
ligament and CFA, extent of SFA disease is now
confirmed and endovascular option is ruled out for
left side
9 To determine extent of iliac disease DUS is incomplete for left leg, need to define
involvement of CFA on right side and possibility of
proximal endovascular therapy
Can now be determined Anatomy of left leg and SFA disease, extent of right EIA
and CFA disease and quality for popliteal target can
be determined
10 Inaccurate visualization of left EIA History of surgery and new onset symptoms mandate
need for more definitive imaging. Also, right buttock
symptoms not easily explained by any of these DUS
findings.
Better visualization of left EIA Extent of stenosis left EIA and proximity to CFA
defined. Severe right profunda disease revealed,
including occluded branches, but patent branch
details seen.
11 For evaluation of CFA and SFA for potential profunda
plasty and SFA bypass.
For more complete assessment of CFA, profunda
disease and runoff
Additional information not provided ‘More complete assessment of iliac, CFA and profunda
disease, and runoff
12 Considered not required Considered not required
CFA, Common femoral artery; EIA, external iliac artery; SFA, superficial femoral artery.
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